retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Reports Upcoming wave of hormone-based therapies
Description
Morgan Stanleys late-September downgrade of Novo Nordisk cited stagnant U.S

Diabetes Med (2000) 17(1):339

Kosiborod, M
00967-0/asset/1cda1e69-507e-47d1-ad73-620bcd1cbb66/main.assets/gr2_lrg.jpg)
The drugs are also effective in promoting weight loss if taken according to their treatment plan, which means patients should take the drugs continuously for at least 12 weeks

& Leech, C
